In addition, up to 40% of ABC-DLBCL harbor a canonical MYD88 L265P mutation that cooperates downstream with BCR signaling in an NF-κB–activating supercomplex (Ngo et al., 2011; Phelan et al., 2018; Reddy et al., 2017; Schmitz et al., 2018). The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.